Immune checkpoint molecules, such as CTLA-4 and PD-1, disrupt antitumor immunity by attenuating T-cell activation in the event of malignancy, leading to a highly immunosuppressive tumor microenvironment [6]. The gene discussed is PDCD1; the disease is neoplasm.